20 articles
A major review in Nature Medicine explores how CAR cell therapies may achieve deep immune 'reset' in autoimmune diseases by depleting pathogenic B cells.
A Cochrane meta-analysis of 17 RCTs finds blue light TURBT reduces bladder cancer recurrence and progression, especially in intermediate- and high-risk patients.
A new AHA scientific statement outlines evidence-based strategies to optimize heart failure care for older adults navigating frailty, polypharmacy, and multimorbidity.
A translational review outlines how stem cell technologies may finally make hepatocyte-based liver therapies clinically viable.
A Cochrane meta-analysis of 8 RCTs finds most pharmacological treatments fail to improve ataxia scores, though upper limb dexterity may benefit.
Virtual patient replicas built from multimodal data may slash trial costs, generate synthetic control arms, and predict treatment response in IBD.
Expert reviews compare leading senolytic and NAD+ supplement brands on ingredients, evidence quality, and value.
A Circulation review from Harvard proposes the 'target trial framework' to improve how observational data is used to assess cardiovascular device safety and effectiveness.
Expert reviews confirm NR and NMN raise blood NAD+, but longevity proof remains elusive and product quality varies widely.
A landmark AHA scientific statement tackles inconsistent cardiovascular safety reporting in oncology trials with a unified framework.
Aging disrupts gut microbiota and mTOR signaling, crippling vaccine responses — but targeted interventions may reverse this.
A Cochrane review of two RCTs finds very low-certainty evidence that IGF-1 neither prevents nor worsens retinopathy of prematurity in extremely preterm infants.
A product review breaks down the evidence tiers for four popular longevity supplements and rates the best commercial stacks.
New expert reviews compare NMN and NR head-to-head, ranking top products by purity, absorption, and clinical evidence.
A Cochrane review finds only one small RCT on surgical timing for cardiac surgery, with afternoon starts linked to lower troponin release.
A Cochrane meta-analysis of 11 RCTs finds very low-certainty evidence that liver support systems neither reduce mortality nor improve key outcomes in ALF.
A candid breakdown of top NAD+ booster brands reveals strong biomarker data but slim evidence for real longevity outcomes.
Longevity experts endorse short CGM trials for non-diabetics, but RCT evidence remains thin. Here's what the data actually shows.
A Cochrane review of 4 RCTs finds no reliable evidence that adding endovascular stenting to medical therapy prevents stroke or death in vertebral artery stenosis.
Longevity experts endorse CGMs for metabolic optimization, but RCT evidence in non-diabetics is still thin.
